A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped With a favorable safety profile the difference between treatment groups for the primary composite endpoint was not sufficient to generate statistically significant results with the targeted sample size

Conditions

Non Small Cell Lung Cancer
Small-cell Lung Cancer

Interventions

DRUG: ALRN-6924
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Placebo
DRUG: ALRN-6924
DRUG: Topotecan

Sponsor

Aileron Therapeutics, Inc.